The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer

Lung Cancer

Volumn 87, Issue 2, 2015, Pages 169-175

  Arrieta, Oscar ^a   Cardona, Andrés Felipe ^b,c   Corrales, Luis ^d   Campos Parra, Alma Delia ^a   Sánchez Reyes, Roberto ^a   Amieva Rivera, Eduardo ^a   Rodríguez, July ^c   Vargas, Carlos ^b,c   Carranza, Hernán ^b,c   Otero, Jorge ^b,c   Karachaliou, Nikki ^e   Astudillo, Horacio ^f   Rosell, Rafael ^e  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b Institute of Oncology   (Colombia)

^c Foundation for Clinical and Translational Research in Cancer (FICMAC)   (Colombia)

^d HOSPITAL SAN JUAN DE DIOS   (Costa Rica)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

Adenocarcinoma lung cancer; Deletion exon 19; EGFR mutations; EGFR tyrosine kinase inhibitors; L858R mutation

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL; VERY ELDERLY; WORLD HEALTH ORGANIZATION; CANCER GRADING; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; EXON; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PLATINUM; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TREATMENT OUTCOME;

EID: 84922466166     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.12.009     Document Type: Article

References (35)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Pan America Health Organization (PAHO) Lung cancer in the Americas 2013, Available from: http://www.paho.org/hq/index.php?Option=com_docman&task=doc_view&gid=22070&Itemid [accessed June 2014].
3. Arrieta O., Campos-Parra A.D., Zuloaga C., Avilés A., Sánchez-Reyes R., Manríquez M.E., et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol 2012, 8:1228-1234.
4. Arrieta O., Guzmán-de Alba E., Alba-López L.F., Acosta-Espinoza A., Alatorre-Alexander J., Alexander-Meza J.F., et al. Consenso de Cáncer de Pulmón. Rev Invest Clin 2013, 65(Suppl. 1):s5-s84.
5. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 10(346):92-98.
6. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer molecular origins of cancer. N Engl J Med 2008, 25(359):1367-1380.
7. Arrieta O., Cardona A.F., Federico Bramuglia G., Gallo A., Campos-Parra A.D., Serrano S., et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol 2011, 6:1955-1959.
8. Sequist L.V., Bell D.W., Lynch T.J., Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007, 10(25):587-595.
9. Campos-Parra A.D., Zuloaga C., Manríquez M.E., Cardona A., Meneses A., Arrieta O., et al. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am J Clin Oncol 2013, (March). [Publish Ahead of Print]. 10.1097/COC.0b013e318287bb23.
10. Lee H.J., Kim Y.T., Kang C.H., Zhao B., Tan Y., Schwartz L.H., et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 2013, 268:254-264.
11. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
12. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
13. Brandao E.P., Pantarotto M.G., Cruz M. A novel EGFR mutation in exon 18 with high sensitivity to EGFR TKI treatment with reduced dose. J Thorac Oncol 2012, (November):e32. 10.1097/JTO.0b013e31826d8f66.
14. Wu J.Y., Yu C.J., Chang Y.C., Yang C.H., Shih J.Y., Yang P.C., et al. Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011, 17:3812-3821.
15. Lund-Iversen M., Kleinberg L., Fjellbirkeland L., Helland Å., Brustugun O.T., et al. Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol 2012, 7:1471-1473.
16. Arcila M.E., Nafa K., Chaft J.E., Rekhtman N., Lau C., Reva B.A., et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013, 12:220-229.
17. Wu J.Y., Wu S.G., Yang C.H., Gow C.H., Chang Y.L., Yu C.J., et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008, 1(14):4877-4882.
18. Janjigian Y.Y., Smit E.F., Groen H.J., Horn L., Gettinger S., Camidge D.R., et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 2014, 4(September):1036-1045.
19. Campos-Parra A.D., Avilés A., Contreras-Reyes S., Rojas-Marín C.E., Sánchez-Reyes R., Arrieta O., et al. Relevance of the novel IASLC/ATS/ERS classification of lung the novel adenocarcinoma in advanced disease. Eur Respir J 2014, 43(May):1439-1447.
20. Russell P.A., Wainer Z., Wright G.M., Daniels M., Conron M., Williams R.A. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011, 6:1496-1504.
21. Azzoli C.G., Temin S., Aliff T., Baker S., Brahmer J., Johnson D.H., et al. Focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011, 29:3825-3831.
22. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST Guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
23. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
24. Seto T., T.F xT., Nishio M., Goto K., Atagi S., F Y., et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014, 10.1016/S1470-2045(14)70381-X.
25. Yang J.C., Sequist L.V., Schuler M.H., Mok T., Yamamoto N., O'Byrne K.J., et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 LL3 and LUX-Lung 6 LL6) comparing afatinib with chemotherapy (CT). J Clin Oncol 2014, 32:5s. [Suppl.; abstr 8004].
26. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
27. Yang J.C., Shih J.Y., Su W.C., Hsia T.C., Tsai C.M., Ou S.H., et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13:539-548.
28. Yoshizawa A., Motoi N., Riely G.J., Sima C.S., Gerald W.L., Kris M.G., et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011, 24:653-664.
29. Russell P.A., Wainer Z., Wright G.M., Daniels M., Conron M., Williams R.A., et al. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011, 6:1496-1504.
30. Warth A., Muley T., Meister M., Stenzinger A., Thomas M., Schirmacher P., et al. The novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012, 1(30):1438-1446.
31. Hung J.J., Yeh Y.C., Jeng W.J., Wu K.J., Huang B.S., Wu Y.C., et al. Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol 2014, 32(August):2357-2364.
32. Yasuda H., Kobayashi S., Costa D.B. EGFR exon 20 insertion mutations in non-small-cell cancer: preclinical data and clinical implications. Lancet Oncol 2012, 13:23-31.
33. Sutto L., Gervasio F.L. Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase. Proc Natl Acad Sci 2013, 110:10616-10621.
34. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 23(3):75ra26.
35. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(September):947-957.